Successful translation of research to applications in Biotech

Presented by the Australian Academy of Technological Sciences and Engineering's Victorian Division

Event details

Thursday 6 October 2022

6:30 – 7:30PM AEDT – Presentation
7:30 – 9:00PM AEDT – Optional Dinner


Presentation – Free
Optional Dinner – $32.50


Graduate House University of Melbourne 220 Leicester Street Carlton 3053


> Professor Sally McArthur FTSE, Director, Institute for Frontier Materials (IFM) at Deakin University

> Dr Andrew Nash FTSE, Chief Scientific Officer & Senior Vice President Research, CSL Limited


Presented by the Australian Academy of Technological Sciences & Engineering’s (ATSE) Victorian Division


Join us to hear about successful research translation in biotech from 2021 new ATSE Fellows Professor Sally McArthur FTSE and Dr Andrew Nash FTSE.

Bioengineering is an inherently multidisciplinary field – science and technology knowledge is brought together with insights from clinical practice and where we aim to create both useful and usable solutions. Professor McArthur’s talk will introduce you to two very different projects: one an end-user-led innovation approach and the other a community building exercise to integrate research and development knowledge that supports the development of new medical device companies.

Dr Nash’s talk is about the increasing focus on the need to translate the innovative medical research undertaken within Australia’s academic sector into outcomes that benefit the health and wellbeing of the community. Australia is known for its internationally competitive, high-quality scientific outputs however, compared with peer countries such as the UK, Canada and the US, the infrastructure and skills to support the translation process in Australia remain relatively underdeveloped.

Sally MacArthur Current Photo
Professor Sally McArthur FTSE

Director, Institute for Frontier Materials (IFM) at Deakin University

Sally McArthur is the Director of the Institute for Frontier Materials (IFM) at Deakin University. As an engineering researcher Sally has obtained approximately $25M in funding from research councils, industry and government in the UK and Australia. She is passionate about exploring new ways to link industry and academia to create new products and services and, critically, a new generation of entrepreneurial, innovative and internationally connected graduates.

Sally spent the last 14 years at Swinburne University of Technology in a variety of roles including Associate Dean of STEM Research, Director of the Swinburne Innovation Precinct, Director of the Manufacturing Futures Research Institute and Professor of BioEngineering.  Sally was a Lecturer and Senior Lecturer for 6 years at the University of Sheffield in the UK after completing her Post-Doctoral Studies at the University of Washington in Seattle. She obtained her PhD from the University of New South Wales working with contact lens manufacturer Ciba Vision and CSIRO. She obtained her MEng Sci (Biomedical Engineering) and B.Eng (Materials Engineering) from Monash University.

Picture 1
Dr Andrew Nash FTSE

Chief Scientific Officer & Senior Vice President Research, CSL Limited

Andrew Nash, PhD is the Chief Scientific Officer and Senior Vice President, Research at CSL Limited and is an Honorary Associate Professor at the University of Melbourne. He completed his PhD in immunology at The University of Melbourne in 1988 and, after moving to the Centre for Animal Biotechnology in the Faculty of Veterinary Science, developed and led a research group focused on basic and applied aspects of cytokine biology.

In 1996 he joined the ASX listed biotechnology company Zenyth Therapeutics (then Amrad Corporation) as a senior scientist and subsequently held a number of positions including Director of Biologicals Research and Chief Scientific Officer.  In July of 2005 he was appointed Chief Executive Officer of Zenyth, a position which he held up until the acquisition of Zenyth by CSL Limited in November 2006.  Following the acquisition he was appointed as CSL’s SVP, Research and is currently based at the Bio21 Institute where he leads a large global effort focused on the discovery and development of new protein, cell and gene-based medicines to treat serious human disease.  He was appointed as CSL’s Chief Scientific Officer in 2020.